Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?

NCT ID NCT03531736

Ongoing ⭐️ CURE ⭐️ Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial tests a new, lower-intensity combination of chemotherapy and radiation before a donor stem cell transplant for people with high-risk blood cancers or aplastic anemia. The goal is to see if this approach is safe enough to allow the donor cells to take hold and cure the disease. The study uses a special method to remove certain immune cells from the donor graft, which may reduce complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of chemotherapy (fludarabine, cyclophosphamide), low-dose total body irradiation, antithymocyte globulin, rituximab, and a stem cell transplant from a donor with a special T-cell depletion process
What this could lead to
If this approach works, it could offer a safer, more effective way to cure certain blood cancers and aplastic anemia using donor stem cells.
What could go wrong
This is a very early pilot study with only 17 participants, so the results may not apply to everyone. The T-cell depletion method is not yet FDA-approved, and there are risks like infection, graft failure, or side effects from the conditioning regimen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia aplastic anemia B-cell chronic lymphocytic leukemia chronic myelogenous leukemia, BCR-ABL1 positive chronic myelomonocytic leukemia myelodysplastic syndrome myelodysplastic/myeloproliferative neoplasm myeloproliferative neoplasm non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOID DISEASES

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    Middletown, New Jersey, 07748, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.